More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $260.21 |
|
|||
| Open | $260.21 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $260.21 | ||||
| Day Low | $260.21 | ||||
| P/E | 56.44 | ||||
| EPS | $4.61 | ||||
| Volume | 159 | ||||
- AbbVie's etentamig meets Phase 3 endpoints in multiple myeloma trial
- AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multi
- Form 8-K AbbVie Inc. For: Sep 03
- AbbVie completes $10.9B acquisition of Apogee Therapeutics
- AbbVie Completes Acquisition of Apogee Therapeutics
- AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
- AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
- AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
